ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes

About this Attention Score

• In the top 25% of all research outputs scored by Altmetric
• Among the highest-scoring outputs from this source (#41 of 1,214)
• High Attention Score compared to outputs of the same age (94th percentile)
• High Attention Score compared to outputs of the same age and source (87th percentile)